HIV researcher David Ho has a new line of attack on SARS-CoV-2, and his fledgling startup is gunning for the clinic
The famed AIDS researcher David Ho started off the Covid-19 pandemic working to develop an antibody against the SARS-CoV-2 virus, but now he’s behind a new biotech that’s taking a slightly different approach to fight the disease.
Ho is a co-founder of RenBio, which pulled in its first fundraise Thursday morning with a $24 million Series A, the company announced. The biotech is pouring its first efforts into a bispecific antibody targeting two sites on the SARS-CoV-2 spike protein, and is touting activity against several Covid-19 variants of concern including strains originating from the UK, South Africa and Brazil, among others.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.